The efficacy of novel metabolic targeted agents and natural plant drugs for nonalcoholic fatty liver disease treatment
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The efficacy of novel metabolic targeted agents and natural plant drugs for nonalcoholic fatty liver disease treatment
Authors
Keywords
-
Journal
MEDICINE
Volume 100, Issue 12, Pages e24884
Publisher
Ovid Technologies (Wolters Kluwer Health)
Online
2021-03-24
DOI
10.1097/md.0000000000024884
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effects of curcuminoids on inflammatory status in patients with non-alcoholic fatty liver disease: A randomized controlled trial
- (2020) Maryam Saberi-Karimian et al. COMPLEMENTARY THERAPIES IN MEDICINE
- Cenicriviroc Treatment for Adults with Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study
- (2020) Vlad Ratziu et al. HEPATOLOGY
- Selonsertib for Patients with Bridging Fibrosis or Compensated Cirrhosis Due to NASH: Results from Randomized Ph III STELLAR Trials
- (2020) Stephen A. Harrison et al. JOURNAL OF HEPATOLOGY
- A pilot study of the effect of curcumin on epigenetic changes and DNA damage among patients with non-alcoholic fatty liver disease: A randomized, double-blind, placebo-controlled, clinical trial
- (2020) Mitra Hariri et al. COMPLEMENTARY THERAPIES IN MEDICINE
- Evolving role for pharmacotherapy in NAFLD/NASH
- (2020) Suzanna L. Attia et al. CTS-Clinical and Translational Science
- A pilot study of the effect of phospholipid curcumin on serum metabolomic profile in patients with non-alcoholic fatty liver disease: a randomized, double-blind, placebo-controlled trial
- (2019) Saeed Chashmniam et al. EUROPEAN JOURNAL OF CLINICAL NUTRITION
- Does turmeric/curcumin supplementation improve serum alanine aminotransferase and aspartate aminotransferase levels in patients with nonalcoholic fatty liver disease? A systematic review and meta-analysis of randomized controlled trials
- (2019) Reza Goodarzi et al. PHYTOTHERAPY RESEARCH
- Nano-curcumin improves glucose indices, lipids, inflammation, and Nesfatin in overweight and obese patients with non-alcoholic fatty liver disease (NAFLD): a double-blind randomized placebo-controlled clinical trial
- (2019) Seyed Ali Jazayeri-Tehrani et al. Nutrition & Metabolism
- No beneficial effects of resveratrol supplementation on atherogenic risk factors in patients with nonalcoholic fatty liver disease
- (2019) L. Farzin et al. INTERNATIONAL JOURNAL FOR VITAMIN AND NUTRITION RESEARCH
- Effects of phytosomal curcumin on anthropometric parameters, insulin resistance, cortisolemia and non-alcoholic fatty liver disease indices: a double-blind, placebo-controlled clinical trial
- (2019) Arrigo F. G. Cicero et al. EUROPEAN JOURNAL OF NUTRITION
- Treatment options for nonalcoholic fatty liver disease
- (2019) Amir Anushiravani et al. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
- Unexpected Rapid Increase in the Burden of Nonalcoholic Fatty Liver Disease in China From 2008 to 2018: A Systematic Review and Meta‐Analysis
- (2019) Feng Zhou et al. HEPATOLOGY
- Turmeric and chicory seed have beneficial effects on obesity markers and lipid profile in non-alcoholic fatty liver disease (NAFLD)
- (2019) Aida Ghaffari et al. INTERNATIONAL JOURNAL FOR VITAMIN AND NUTRITION RESEARCH
- Curcumin and inflammation in non-alcoholic fatty liver disease: a randomized, placebo controlled clinical trial
- (2019) Saeede Saadati et al. BMC GASTROENTEROLOGY
- Contribution of a genetic risk score to clinical prediction of hepatic steatosis in obese children and adolescents
- (2019) Chiara Zusi et al. DIGESTIVE AND LIVER DISEASE
- Curcuminoids plus piperine improve nonalcoholic fatty liver disease: A clinical trial
- (2019) Yunes Panahi et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Effect of Phytosomal Curcumin on Circulating Levels of Adiponectin and Leptin in Patients with Non-Alcoholic Fatty Liver Disease: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
- (2019) Seyed Reza Mirhafez et al. Journal of Gastrointestinal and Liver Diseases
- CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients
- (2019) Paul J. Pockros et al. LIVER INTERNATIONAL
- Silymarin in non-cirrhotics with non-alcoholic steatohepatitis: A randomized, double-blind, placebo controlled trial
- (2019) Victor J. Navarro et al. PLoS One
- The effects of curcumin supplementation on liver function, metabolic profile and body composition in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials
- (2019) Mohammad Jalali et al. COMPLEMENTARY THERAPIES IN MEDICINE
- PNPLA3 I148M Polymorphism in Patients with Nonalcoholic Fatty Liver Disease, Obesity and Prediabetes
- (2019) Vera Karamfilova et al. Journal of Gastrointestinal and Liver Diseases
- Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis
- (2019) Mohammad Shadab Siddiqui et al. JOURNAL OF HEPATOLOGY
- Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
- (2019) Zobair M Younossi et al. LANCET
- The effects of curcumin supplementation on body mass index, body weight, and waist circumference in patients with nonalcoholic fatty liver disease: A systematic review and dose–response meta‐analysis of randomized controlled trials
- (2019) Nima Baziar et al. PHYTOTHERAPY RESEARCH
- Nonalcoholic Fatty Liver Disease: A Challenge from Mechanisms to Therapy
- (2019) Giovanni Tarantino et al. Journal of Clinical Medicine
- PPAR Agonists and Metabolic Syndrome: An Established Role?
- (2018) Margherita Botta et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Critical quality evaluation of network meta-analyses in dental care
- (2018) Dae-Woo Lee et al. JOURNAL OF DENTISTRY
- Bile acids in glucose metabolism in health and disease
- (2018) Hagit Shapiro et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Comparison of Calorie-Restricted Diet and Resveratrol Supplementation on Anthropometric Indices, Metabolic Parameters, and Serum Sirtuin-1 Levels in Patients With Nonalcoholic Fatty Liver Disease: A Randomized Controlled Clinical Trial
- (2018) Somayyeh Asghari et al. JOURNAL OF THE AMERICAN COLLEGE OF NUTRITION
- Mechanisms of NAFLD development and therapeutic strategies
- (2018) Scott L. Friedman et al. NATURE MEDICINE
- Global Perspectives on Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis
- (2018) Zobair Younossi et al. HEPATOLOGY
- The effects of curcumin on the metabolic parameters of non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials
- (2018) Zhongcao Wei et al. Hepatology International
- Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis
- (2017) Parambir S. Dulai et al. HEPATOLOGY
- Systematic Review and Meta-Analysis Resveratrol supplementation in patients with non-alcoholic fatty liver disease: systematic review and meta-analysis
- (2017) Journal of Gastrointestinal and Liver Diseases
- Turmeric Supplementation Improves Serum Glucose Indices and Leptin Levels in Patients with Nonalcoholic Fatty Liver Diseases
- (2017) Roya Navekar et al. JOURNAL OF THE AMERICAN COLLEGE OF NUTRITION
- The therapeutic effect of silymarin in the treatment of nonalcoholic fatty disease
- (2017) Sheng Zhong et al. MEDICINE
- Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
- (2016) Vlad Ratziu et al. GASTROENTEROLOGY
- Curcumin Lowers Serum Lipids and Uric Acid in Subjects With Nonalcoholic Fatty Liver Disease
- (2016) Yunes Panahi et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
- Treatment of Non-alcoholic Fatty Liver Disease with Curcumin: A Randomized Placebo-controlled Trial
- (2016) Sepideh Rahmani et al. PHYTOTHERAPY RESEARCH
- Placebo-controlled, randomised clinical trial: high-dose resveratrol treatment for non-alcoholic fatty liver disease
- (2016) Sara Heebøll et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study
- (2015) Forouzan Faghihzadeh et al. BRITISH JOURNAL OF NUTRITION
- Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: A randomized controlled trial
- (2015) Shihui Chen et al. DIGESTIVE AND LIVER DISEASE
- Resveratrol Does Not Benefit Patients With Nonalcoholic Fatty Liver Disease
- (2014) Veronique S. Chachay et al. Clinical Gastroenterology and Hepatology
- Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
- (2013) Sunder Mudaliar et al. GASTROENTEROLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation